On January 3, 2014 Eleison Pharmaceuticals LLC, a specialty pharmaceutical company developing life-saving therapeutics for rare cancers, reported that it has passed the half-way point for enrollment in the first stage of its ongoing Phase II study of ILC (Inhaled Lipid-complexed Cisplatin), for the treatment of patients with pediatric osteosarcoma (bone cancer) (Press release, Eleison Pharmaceuticals, JAN 3, 2014, View Source [SID1234517400]). The single-arm trial employs a Simon two-stage design and is evaluating the safety and efficacy of ILC. Currently, eight centers in the U.S. are open for patient enrollment, and additional sites are expected to open in the coming weeks. More information about the study may be found at the www.clinicaltrials.gov website.
"Osteosarcoma often spreads to the lungs, which unfortunately is difficult to treat and has a poor prognosis," commented Dr. Forrest Anthony, CMO of Eleison Pharmaceuticals. "ILC has been designed to treat patients with lung metastases, and thus the ongoing Phase II study is enrolling patients who have recently experienced a first or second pulmonary recurrence," indicated Dr. Anthony.
About

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!